195 related articles for article (PubMed ID: 12069581)
21. Possible existence of common internalization mechanisms among arginine-rich peptides.
Suzuki T; Futaki S; Niwa M; Tanaka S; Ueda K; Sugiura Y
J Biol Chem; 2002 Jan; 277(4):2437-43. PubMed ID: 11711547
[TBL] [Abstract][Full Text] [Related]
22. Structural variety of arginine-rich RNA-binding peptides.
Tan R; Frankel AD
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5282-6. PubMed ID: 7777498
[TBL] [Abstract][Full Text] [Related]
23. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement.
Nakase I; Niwa M; Takeuchi T; Sonomura K; Kawabata N; Koike Y; Takehashi M; Tanaka S; Ueda K; Simpson JC; Jones AT; Sugiura Y; Futaki S
Mol Ther; 2004 Dec; 10(6):1011-22. PubMed ID: 15564133
[TBL] [Abstract][Full Text] [Related]
24. Cell-Surface Interactions on Arginine-Rich Cell-Penetrating Peptides Allow for Multiplex Modes of Internalization.
Futaki S; Nakase I
Acc Chem Res; 2017 Oct; 50(10):2449-2456. PubMed ID: 28910080
[TBL] [Abstract][Full Text] [Related]
25. Methodological and cellular aspects that govern the internalization mechanisms of arginine-rich cell-penetrating peptides.
Nakase I; Takeuchi T; Tanaka G; Futaki S
Adv Drug Deliv Rev; 2008 Mar; 60(4-5):598-607. PubMed ID: 18045727
[TBL] [Abstract][Full Text] [Related]
26. Tat peptide-mediated cellular delivery: back to basics.
Brooks H; Lebleu B; Vivès E
Adv Drug Deliv Rev; 2005 Feb; 57(4):559-77. PubMed ID: 15722164
[TBL] [Abstract][Full Text] [Related]
27. Orientation and affinity of HIV-1 Tat fragments in Tat-TAR complex determined by fluorescence resonance energy transfer.
Cao H; Tamilarasu N; Rana TM
Bioconjug Chem; 2006; 17(2):352-8. PubMed ID: 16536465
[TBL] [Abstract][Full Text] [Related]
28. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells.
Thorén PE; Persson D; Isakson P; Goksör M; Onfelt A; Nordén B
Biochem Biophys Res Commun; 2003 Jul; 307(1):100-7. PubMed ID: 12849987
[TBL] [Abstract][Full Text] [Related]
29. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat.
Gabizon R; Mor M; Rosenberg MM; Britan L; Hayouka Z; Kotler M; Shalev DE; Friedler A
Biopolymers; 2008; 90(2):105-16. PubMed ID: 18189286
[TBL] [Abstract][Full Text] [Related]
30. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate.
Violini S; Sharma V; Prior JL; Dyszlewski M; Piwnica-Worms D
Biochemistry; 2002 Oct; 41(42):12652-61. PubMed ID: 12379107
[TBL] [Abstract][Full Text] [Related]
31. Activity of synthetic peptides from the Tat protein of human immunodeficiency virus type 1.
Frankel AD; Biancalana S; Hudson D
Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7397-401. PubMed ID: 2552444
[TBL] [Abstract][Full Text] [Related]
32. An RNA-binding peptide from bovine immunodeficiency virus Tat protein recognizes an unusual RNA structure.
Chen L; Frankel AD
Biochemistry; 1994 Mar; 33(9):2708-15. PubMed ID: 8117736
[TBL] [Abstract][Full Text] [Related]
33. Selection of TAR RNA-binding chameleon peptides by using a retroviral replication system.
Xie B; Calabro V; Wainberg MA; Frankel AD
J Virol; 2004 Feb; 78(3):1456-63. PubMed ID: 14722301
[TBL] [Abstract][Full Text] [Related]
34. Arginine-rich cell-penetrating peptides.
Schmidt N; Mishra A; Lai GH; Wong GC
FEBS Lett; 2010 May; 584(9):1806-13. PubMed ID: 19925791
[TBL] [Abstract][Full Text] [Related]
35. Site-specific cross-linking of amino acids in the basic region of human immunodeficiency virus type 1 Tat peptide to chemically modified TAR RNA duplexes.
Farrow MA; Aboul-ela F; Owen D; Karpeisky A; Beigelman L; Gait MJ
Biochemistry; 1998 Mar; 37(9):3096-108. PubMed ID: 9485463
[TBL] [Abstract][Full Text] [Related]
36. Cell-penetrating peptides: tools for intracellular delivery of therapeutics.
Deshayes S; Morris MC; Divita G; Heitz F
Cell Mol Life Sci; 2005 Aug; 62(16):1839-49. PubMed ID: 15968462
[TBL] [Abstract][Full Text] [Related]
37. NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat.
Mujeeb A; Bishop K; Peterlin BM; Turck C; Parslow TG; James TL
Proc Natl Acad Sci U S A; 1994 Aug; 91(17):8248-52. PubMed ID: 8058789
[TBL] [Abstract][Full Text] [Related]
38. Flow cytometric screening of cell-penetrating peptides for their uptake into embryonic and adult stem cells.
Manceur A; Wu A; Audet J
Anal Biochem; 2007 May; 364(1):51-9. PubMed ID: 17379177
[TBL] [Abstract][Full Text] [Related]
39. Molecular transporters: synthesis of oligoguanidinium transporters and their application to drug delivery and real-time imaging.
Goun EA; Pillow TH; Jones LR; Rothbard JB; Wender PA
Chembiochem; 2006 Oct; 7(10):1497-515. PubMed ID: 16972294
[No Abstract] [Full Text] [Related]
40. Aqueous solution structure of a hybrid lentiviral Tat peptide and a model of its interaction with HIV-1 TAR RNA.
Mujeeb A; Parslow TG; Yuan YC; James TL
J Biomol Struct Dyn; 1996 Feb; 13(4):649-60. PubMed ID: 8906885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
